Multicenter, open-label, randomized study in patients with ovarian cancer
Active, no longer recruiting
Phase of Trial: Phase II
Latest Information Update: 23 Feb 2018
At a glance
- Drugs Nivolumab (Primary) ; Doxorubicin; Gemcitabine
- Indications Ovarian cancer
- Focus Therapeutic Use
- Sponsors Ono Pharmaceutical
- 12 Feb 2018 Status changed from recruiting to active, no longer recruiting.
- 22 May 2017 Planned number of patients changed from 116 to 300.
- 22 May 2017 Planned End Date changed from 1 May 2019 to 1 Jul 2020.